Treatment Options for Multiple Sclerosis: Current and Emerging Therapies

Kristen M. Gawronski, Pharm.D.; Michelle M. Rainka, Pharm.D.; Malti J. Patel, M.D.; Francis M. Gengo, Pharm.D., FCP


Pharmacotherapy. 2010;30(9):916-927. 

In This Article


Although all of the currently available therapies for multiple sclerosis are parenteral, much research has been focused on developing new and effective oral drugs for treatment of this disease. Both monoclonal antibodies and immunomodulators are being developed for patients with RRMS, PPMS, and SPMS. A list of the agents discussed above and their proposed places in therapy is presented in Table 3. Investigational agents appear to demonstrate similar or improved efficacy when compared with the current standards of treatment, and they may become first-line therapies pending complete safety information. Within the next few years, the first oral drug to treat multiple sclerosis should be available. This marks a new frontier in the treatment of multiple sclerosis. Orally administered drugs are likely to reach patients who are not treated because of compliance issues or who have forms of multiple sclerosis for which we do not currently have FDA-approved treatments. However, it is expected that parenteral drugs will remain in demand due to proven efficacy. Patients who are clinically stable with currently available therapies may be unlikely to switch. These new treatments will broaden the pool of available drug therapies. They will give patients the opportunity to take a drug that is safe, effective, and easier to administer than currently available disease-modifying agents.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: